National Taskforce for Combating the Coronavirus (COVID-19), Supreme health council, Manama, Bahrain; University of Manchester, Manchester, UK.
Department of Family and Community Medicine, Arabian Gulf University, Manama, Bahrain.
Int J Infect Dis. 2022 Oct;123:9-16. doi: 10.1016/j.ijid.2022.07.075. Epub 2022 Aug 2.
SARS-CoV-2 vaccination has been shown to reduce infection severity; however, the reinfection frequency among unvaccinated, partially vaccinated, and fully vaccinated individuals remains unclear. This study aims to elucidate the rates of and factors associated with such occurrences.
This retrospective epidemiological report included 1362 COVID-19 reinfection cases in Bahrain between April 2020 and July 2021. We analyzed differences in disease severity and reinfection characteristics among various vaccination statuses: fully vaccinated, interrupted vaccination, one-dose vaccination, postreinfection vaccination, and unvaccinated.
Reinfection cases increased from zero per month in April-June 2020 to a sharp peak of 579 in May 2021. A significantly larger proportion of reinfected individuals were male (60.3%, P <0.0001). Reinfection episodes were highest among those 30-39 years of age (29.7%). The fewest reinfection episodes occurred at 3-6 months after the first infection (20.6%) and most occurred ≥9 months after the initial infection (46.4%). Most individuals were asymptomatic during both episodes (35.7%). Reinfection disease severity was mild, with vaccinated patients less likely to have symptomatic reinfection (odds ratio 0.71, P = 0.004). Only 6.6% of reinfected patients required hospitalization. One death was recorded; the patient belonged to the unvaccinated group.
Vaccine-induced immunity and previous infection with or without vaccination were effective in reducing reinfection disease severity.
SARS-CoV-2 疫苗接种已被证明可降低感染严重程度;然而,未接种、部分接种和完全接种人群的再感染频率尚不清楚。本研究旨在阐明这些情况的发生频率和相关因素。
本回顾性流行病学报告纳入了 2020 年 4 月至 2021 年 7 月期间在巴林发生的 1362 例 COVID-19 再感染病例。我们分析了不同疫苗接种状态(完全接种、中断接种、一剂接种、再感染后接种和未接种)下疾病严重程度和再感染特征的差异。
再感染病例从 2020 年 4 月至 6 月的每月零例增加到 2021 年 5 月的 579 例高峰。再感染人群中男性比例显著更大(60.3%,P<0.0001)。30-39 岁年龄组的再感染病例最多(29.7%)。初次感染后 3-6 个月发生的再感染病例最少(20.6%),而初次感染后≥9 个月发生的再感染病例最多(46.4%)。两次感染期间大多数患者均无症状(35.7%)。再感染疾病严重程度为轻度,接种疫苗的患者发生有症状再感染的可能性较低(比值比 0.71,P=0.004)。仅有 6.6%的再感染患者需要住院治疗。记录到 1 例死亡病例;该患者属于未接种组。
疫苗诱导的免疫和既往感染(无论是否接种疫苗)可有效降低再感染疾病的严重程度。